Flecainide is a class IC antiarrhythmic drug used for managing atrial fibrillation and specific ventricular arrhythmias, but is contraindicated in patients with ischemic structural heart disease.
Flecainide is a versatile antiarrhythmic drug useful for atrial fibrillation and specific channelopathies, though contraindicated in ischemic structural heart disease.
Flecainide is a IC antiarrhythmic drug with a history of more than 30 years, nowadays it is widely used for the management of acute episodes of atrial fibrillation and sinus rhythm maintenance, however, firstly was approved for the treatment of ventricular arrhythmia and later due to the results of the Cardiac Arrhythmia Suppression Trial was contraindicated in patients with ischemic structural heart disease. Of note, flecainide use is feasible in different clinical situations, such as catecholaminergic polymorphic ventricular tachycardia, for unmasking Brugada syndrome, and for patients with long QT syndrome. In our country, flecainide is new for clinical use; therefore, the clinical experience with flecainide is limited. In this review article, we aim to describe the use of flecainide and its role in the management of cardiac arrhythmias.
Leandro et al. (Thu,) conducted a review in Cardiac arrhythmias. Flecainide was evaluated. Flecainide is a class IC antiarrhythmic drug used for managing atrial fibrillation and specific ventricular arrhythmias, but is contraindicated in patients with ischemic structural heart disease.